The indexed literature does not answer the question. No independent randomised trial was found, and the efficacy claims in commerce trace back to manufacturer and formulation documentation rather than peer-reviewed studies.

What is SNAP-8 supposed to do?

It is modelled on the N-terminal end of SNAP-25 and is proposed to compete for a place in the SNARE complex, reducing the efficiency of neurotransmitter release at the neuromuscular junction — the same biology botulinum toxin acts on, from outside and far more weakly.

Is SNAP-8 the same as Botox?

No. Botulinum toxin is a bacterial protein that cleaves SNARE proteins enzymatically and is injected. SNAP-8 is a short synthetic peptide proposed to interfere with complex assembly, studied as a topical ingredient.

How does SNAP-8 relate to Argireline?

It extends the Argireline sequence — eight residues rather than six. They are related molecules and a finding about one is not evidence about the other.

Is SNAP-8 studied as an injectable?

No. What published work exists concerns formulations applied to skin. It is supplied here as a laboratory reagent for research use only, not for human or veterinary use.

Research guides

SNAP-8 acetyl octapeptide-3: what research says

A topical cosmetic peptide with a coherent SNARE mechanism and almost no independent indexed literature. The absence of published work is the honest headline.

Available in the catalogue

Supplied as research material. Sizes and pricing are on the product page. Availability is not a statement about what a compound does.

SNAP-8
Cosmetic & Dermal

This is the shortest article in this section because there is very little published to report, and saying so plainly is more useful than padding the gap with mechanism speculation.

What the molecule is

An eight-amino-acid peptide extending the sequence of Argireline, developed as a topical cosmetic ingredient. It appears in ingredient listings as acetyl octapeptide-3 or acetyl glutamyl heptapeptide-1.

The proposed mechanism

It is modelled on the N-terminal end of SNAP-25, a protein in the SNARE complex that vesicles use to release neurotransmitter. By competing for a place in that complex it is proposed to reduce the efficiency of release at the neuromuscular junction — aimed at the same biology as botulinum toxin, from the outside and far more weakly.

The mechanism is coherent as a piece of biochemistry. Whether a peptide of this size applied to intact skin reaches the neuromuscular junction in any meaningful quantity is a separate question, and it is the question the published literature does not answer.

What is not there

A search of the indexed biomedical literature for this compound under its names returns essentially nothing: no independent randomised trial, no controlled clinical study, no pharmacokinetic work establishing skin penetration. What exists is largely formulation and supplier documentation, which is not the same category of evidence and should not be cited as if it were.

An empty findings list on this page is not an oversight. It is the accurate representation of a compound that is widely sold and barely studied, and it is the reason this article exists rather than being folded into a sentence somewhere else.

What studies reported

Each entry states what a study examined and the model it used. Nothing below describes an outcome for a person.

Everything below is drawn from published research, and each entry names the model the study used. Approval status varies by compound and by country, and nothing described here is supplied as a medicine or for use in a person.

Adverse and null findings reported

No dedicated safety study has been published for this compound. That is not a finding that none exists — it means the question has not been asked in print, and the gaps below say so.

What the research does not establish

An absence cannot be cited, so these are stated plainly. They are the part of the picture that silence would otherwise hide.

Both citation lists above are empty because a search of the indexed literature under SNAP-8, acetyl octapeptide-3 and acetyl glutamyl heptapeptide-1 did not return studies that could be verified as being about this compound. Nothing was found; that is different from nothing existing, and different again from nothing having been looked for.
No independent randomised controlled trial of this ingredient has been published.
No published pharmacokinetic work establishes whether an eight-residue peptide applied to intact skin reaches the neuromuscular junction at all, which is the assumption the entire proposed mechanism rests on.
The efficacy claims attached to this ingredient in commerce originate from manufacturer and formulation documentation rather than from peer-reviewed independent studies.
The published work in this area concerns formulations applied to skin. Nothing addresses this material in any other context, and it should not be read as if it did.
Its relationship to Argireline — a longer-studied relative — is structural. A finding about one peptide is not automatically a finding about the other.

Common questions

Does SNAP-8 work?: The indexed literature does not answer the question. No independent randomised trial was found, and the efficacy claims in commerce trace back to manufacturer and formulation documentation rather than peer-reviewed studies.
What is SNAP-8 supposed to do?: It is modelled on the N-terminal end of SNAP-25 and is proposed to compete for a place in the SNARE complex, reducing the efficiency of neurotransmitter release at the neuromuscular junction — the same biology botulinum toxin acts on, from outside and far more weakly.
Is SNAP-8 the same as Botox?: No. Botulinum toxin is a bacterial protein that cleaves SNARE proteins enzymatically and is injected. SNAP-8 is a short synthetic peptide proposed to interfere with complex assembly, studied as a topical ingredient.
How does SNAP-8 relate to Argireline?: It extends the Argireline sequence — eight residues rather than six. They are related molecules and a finding about one is not evidence about the other.
Is SNAP-8 studied as an injectable?: No. What published work exists concerns formulations applied to skin. It is supplied here as a laboratory reagent for research use only, not for human or veterinary use.

Compounds covered

The reference page for each compound this article discusses.

SNAP-8

GHK-Cu copper peptide: what the research says
The copper tripeptide GHK-Cu has the strongest published evidence of any repair peptide here, spanning wound models, gene expression and cosmetic dermatology.
Melanotan-1 (afamelanotide): what the research says
Approved in the EU and US as Scenesse for a rare light-sensitivity disorder. What the trial measured, and why the approval is narrower than it sounds.
How to reconstitute lyophilised peptides
How to reconstitute a lyophilised peptide with bacteriostatic water without damaging it: why you run the liquid down the vial wall and never shake it.

About this article

Everything reported here comes from published research, and each finding names the model the study used — cell culture, rat, or human. Findings in one model do not transfer to another, most of the work described is preclinical, and none of it is a claim that a compound is safe or effective for any purpose. Nothing on this page describes doses, routes of administration, or use in a person.

Approval status varies by compound and by country. A few of the substances described are the active ingredient of medicines authorised in the EU; most have no marketing authorisation anywhere and have never been assessed by a regulator. Neither is supplied as a medicine here. All material supplied by ASSAY is sold for in-vitro laboratory research only, and is not a drug, food, cosmetic or medical device, and not for human or veterinary use.

All guides